Abnormal BTLA expression, particularly within the tumor microenvironment (TME) and specifically on tumor-infiltrating lymphocytes (TILs), has been observed in diverse cancers and is frequently associated with impaired anti-tumor immune responses. The gene discussed is BTLA; the disease is cancer.